Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Clinical trial NCT02568553 · COMPLETED

Trial details

NCT number: NCT02568553
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Grade 3b Follicular Lymphoma Recurrent Gray-Zone Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mediastinal Lymphoma Recurrent Non-Hodgkin Lymphoma

Start date: 2016-11-15
Primary completion: 2025-11-24
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.